SL651498
SL651498[edit | edit source]
SL651498 is a pharmacological compound that acts as a GABAA receptor positive allosteric modulator. It was developed by the pharmaceutical company Sanofi-Aventis and is primarily used in research settings to study its effects on the central nervous system.
Pharmacology[edit | edit source]
SL651498 is known for its selective action on the GABAA receptor subtypes. It exhibits a unique profile by preferentially modulating certain subtypes of the receptor, which are composed of different combinations of alpha, beta, and gamma subunits. This selectivity is thought to contribute to its distinct pharmacological effects compared to other benzodiazepines.
The compound has been shown to produce anxiolytic, anticonvulsant, and muscle relaxant effects in preclinical studies. However, unlike traditional benzodiazepines, SL651498 is reported to have a reduced potential for sedation and ataxia, making it a compound of interest for developing new anxiolytic medications with fewer side effects.
Mechanism of Action[edit | edit source]
SL651498 acts as a positive allosteric modulator at the GABAA receptor, enhancing the effects of the neurotransmitter gamma-aminobutyric acid (GABA). By binding to specific sites on the receptor, it increases the frequency of chloride ion channel opening events, leading to hyperpolarization of the neuron and decreased neuronal excitability. This mechanism is similar to that of other benzodiazepines, but the selectivity of SL651498 for certain receptor subtypes may result in a different therapeutic and side effect profile.
Research and Development[edit | edit source]
Research on SL651498 has primarily focused on its potential as a therapeutic agent for anxiety disorders and epilepsy. Studies have demonstrated its efficacy in animal models of anxiety and seizure, suggesting that it may offer advantages over existing treatments. However, as of the latest updates, SL651498 has not been approved for clinical use in humans.
The development of SL651498 highlights the ongoing efforts in the field of neuropharmacology to create drugs that target specific receptor subtypes, aiming to maximize therapeutic benefits while minimizing adverse effects.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
